Relevant bibliographies by topics / IRINOTECAN CANCER TREATMENT

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'IRINOTECAN CANCER TREATMENT'

Author: Grafiati
Published: 26 October 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'IRINOTECAN CANCER TREATMENT.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "IRINOTECAN CANCER TREATMENT"

1

Aoki, Masahiko, Hirokazu Shoji, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, et al. "The hyperprogressive disease during nivolumab treatment or irinotecan treatment in patients with advanced gastric cancer." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 124. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.124.

Full text
Abstract:
124 Background: Nivolumab has demonstrated a survival benefit as a single agent in patients with advanced gastric cancer (AGC) refractory to, or intolerant of, two or more previous regimens in phase III study (ATTRACTION-2). However, an acceleration of tumor growth during immunotherapy, (hyperprogressive disease: HPD), was reported in advanced cancers treated with immunotherapy. The frequency and outcome of HPD in AGC comparing between immunotherapy and cytotoxic agents are little known. The aim of this study was to clarify the prevalence and background of HPD in patients treated with nivolumab or irinotecan. Methods: The subjects of this retrospective study were AGC patients with measurable disease defined by RECIST version 1.1 who were treated with nivolumab or irinotecan at our institution between June 2009 and September 2018, and whose tumors were assessed at least 3 times (during prior therapy, immediately before and after initiating nivolumab or irinotecan). The tumor growth rates (TGR) both before and after nivolumab or irinotecan were calculated as reported (Stéphane Champiat, Clin Cancer Res 2017). HPD was defined as an increase in the TGR exceeding 50% after nivolumab or irinotecan compared with prior therapy. Results: 32 and 66 patients received nivolumab and irinotecan (20 patients received both irinotecan and nivolumab). There were more prior chemotherapy before nivolumab than irinotecan (median: 3 vs 2). The median overall survival (MST) was 4.1 months (95%CI; 4.6-9.3 months) after nivolumab, and 7.0 months (95%CI; 6.3-9.3 months) after irinotecan. There were 9 patients showing HPD (28.1%) after initiating nivolumab and 9 patients (13.5%) after irinotecan (p = 0.0824). There were no differences in background between patients with and without HPD either after nivolumab or irinotecan. 9 patients with HPD showed shorter survival than those without HPD after nivolumab (median: 1.9 vs 6.4 months, p = 0.0007) while there was no such difference after irinotecan (median: 7.3 vs 7.0 months, p = 0.3345). Conclusions: HPD was observed more frequently after initiating nivolumab compared with irinotecan, and was associated with a poor prognosis after nivolumab but not after irinotecan.
APA, Harvard, Vancouver, ISO, and other styles
2

Falcone, Alfredo, Antonello Di Paolo, Gianluca Masi, Giacomo Allegrini, Romano Danesi, Monica Lencioni, Elisabetta Pfanner, Silvia Comis, Mario Del Tacca, and Pierfranco Conte. "Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients." Journal of Clinical Oncology 19, no. 15 (August 1, 2001): 3456–62. http://dx.doi.org/10.1200/jco.2001.19.15.3456.

Full text
Abstract:
PURPOSE: To investigate the sequence effect of irinotecan and a 48-hour infusion of fluorouracil (5-FU) modulated by leucovorin (LV) on the plasma pharmacokinetics of irinotecan and its metabolites, the toxicity profile of this combination, and irinotecan’s maximum-tolerated dose (MTD). PATIENTS AND METHODS: Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV. The reverse sequence was used after 21 days for the second cycle. 5-FU 3,500 mg/m2 was preceded by l-LV 250 mg/m2. Irinotecan 150 mg/m2 (starting dose) was administered to the first three patients. The dose was escalated by 50 mg/m2 in subsequent groups of three to six patients to determine the MTD for both sequences. Pharmacokinetic analysis of irinotecan and its metabolites was performed after each cycle. RESULTS: Toxicities were affected by the sequence of administration of irinotecan and 5-FU, with an improved tolerability for irinotecan followed by 5-FU. The irinotecan MTD was reached at 300 mg/m2 when irinotecan followed 5-FU and at 450 mg/m2 when it preceded 5-FU. In seven of 23 patients who received both sequences at identical irinotecan doses, the dose-limiting toxicity was observed only when irinotecan followed 5-FU. Pharmacokinetic analysis revealed that the administration sequence significantly affected the SN-38 area under the concentration-versus-time curve (AUC), which was 40.1% lower (P < .05) when irinotecan preceded 5-FU. CONCLUSION: The sequence of treatment with irinotecan and infusional 5-FU affects the tolerability of this combination. This can be explained in part by a reduced SN-38 AUC when irinotecan preceded infusional 5-FU. Well-defined 5-FU/irinotecan regimens are needed because the administration sequence or the interval between the agents might affect treatment tolerance and perhaps also activity.
APA, Harvard, Vancouver, ISO, and other styles
3

Vanhoefer, Udo, Andreas Harstrick, Wolf Achterrath, Shousong Cao, Siegfried Seeber, and Youcef M. Rustum. "Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview." Journal of Clinical Oncology 19, no. 5 (March 1, 2001): 1501–18. http://dx.doi.org/10.1200/jco.2001.19.5.1501.

Full text
Abstract:
PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic target in cancer therapy, irinotecan, a semisynthetic TOP-I–interactive camptothecin derivative, has been clinically established in the treatment of colorectal cancer. RESULTS: Irinotecan was investigated as second-line chemotherapy after prior treatment with fluorouracil (FU)-based regimens in two large randomized phase III trials comparing irinotecan with either best supportive care or an infusional FU/leucovorin (LV) regimen. The outcomes of these trials established irinotecan as the standard therapy in the second-line treatment of colorectal cancer. The therapeutic value of irinotecan in the first-line treatment of metastatic colorectal cancer was investigated in two large randomized phase III trials comparing the combination of irinotecan and FU/LV with FU/LV alone. Both trials demonstrated significant superior efficacy for the combination of irinotecan and FU/LV in terms of response rate, median time to disease progression, and median survival time. Consequently, the combination of irinotecan and FU/LV has been approved as first-line chemotherapy for patients with metastatic colorectal cancer and constitutes the reference therapy against which other treatment options must be tested in the future. CONCLUSION: In this review, the clinical rationale and update of the present clinical status of irinotecan in the treatment of colorectal cancer and future prospects of irinotecan-based combinations are discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Bailly, Christian. "Irinotecan: 25 years of cancer treatment." Pharmacological Research 148 (October 2019): 104398. http://dx.doi.org/10.1016/j.phrs.2019.104398.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kockaya, Guvenc, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz, and Saim Kerman. "Treatment cost of metastatic colon cancer in Turkey." Farmeconomia. Health economics and therapeutic pathways 14, no. 1 (January 30, 2013): 19–25. http://dx.doi.org/10.7175/fe.v14i1.472.

Full text
Abstract:
OBJECTIVES: Colon cancer is the third most common in the top cancer incidence list in Europe. In Europe 212,000 patients die every year due to colon cancer. In Turkey 120,000-130,000 new cancer patients are diagnosed every year, 7.1% of whom are diagnosed to have developed colon cancer. Metastases will occur in up to 50% of the patients who are newly diagnosed. Survival appears to be further prolonged to more than 20 months with new pharmaceuticals; however, these new pharmaceuticals increase the total cost of care. The aim of this study is to estimate the cost implications of new colon cancer treatment options for Turkey.METHODS: Gazi University Hospital treatment protocols for colon cancer treatment were used. Cost of FUFA (5 FU/LV), FOLFIRI, FOLFOX, bevacizumab/FUFA, bevacizumab/FOLFIRI, bevacizumab/FOLFOX, irinotecan and irinotecan/cetixumab protocols were calculated. The cost of combination of protocols were calculated depending on a Markov analysis. The exchange rate was US$ 1 for TL 1.5.RESULTS: Depending on the life expectancy the lowest total cost was established by FUVA (US$ 5,359). It was followed by FOLFIRI then FOLFOX and FOLFOX, US$ 14,144 and US$ 16,553, respectively. The lowest cost for each week of life expectancy was established by FUVA with US$ 98.CONCLUSIONS: Only FUFA, FOLFIRI followed by FOLFIX, FOLFIRI/bevacizumab then FOLFOX then cetuximab, FOLFOX/bevacizumab then irinotecan then cetuximab/irinotecan and FOLFIRI/bevacizumab then FOLFOX then cetuximab/irinotecan were under the cost effectiveness curve. In addition no treatments ICER was under the WHO`s threshold for Turkey, except FOLFIRI then FOLFOX compared with FUVA.
APA, Harvard, Vancouver, ISO, and other styles
6

Radajewska, Anna, Helena Moreira, Dorota Bęben, Oliwia Siwiela, Anna Szyjka, Katarzyna Gębczak, Paulina Nowak, et al. "Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment." International Journal of Molecular Sciences 24, no. 11 (May 31, 2023): 9544. http://dx.doi.org/10.3390/ijms24119544.

Full text
Abstract:
Colorectal cancers are one of the leading cancers worldwide and are known for their high potential for metastasis and resistance to therapy. The aim of this study was to investigate the effect of various combination therapies of irinotecan with melatonin, wogonin, and celastrol on drug-sensitive colon cancer cells (LOVO cell line) and doxorubicin-resistant colon cancer stem-like cells (LOVO/DX cell subline). Melatonin is a hormone synthesized in the pineal gland and is responsible for circadian rhythm. Wogonin and celastrol are natural compounds previously used in traditional Chinese medicine. Selected substances have immunomodulatory properties and anti-cancer potential. First, MTT and flow cytometric annexin-V apoptosis assays were performed to determine the cytotoxic effect and the induction of apoptosis. Then, the potential to inhibit cell migration was evaluated using a scratch test, and spheroid growth was measured. The results showed important cytotoxic effects of the drug combinations on both LOVO and LOVO/DX cells. All tested substances caused an increase in the percentage of apoptotic cells in the LOVO cell line and necrotic cells in the LOVO/DX cell subline. The strongest effect on the induction of cancer cell death was observed for the combination of irinotecan with celastrol (1.25 µM) or wogonin (50 µM) and for the combination of melatonin (2000 µM) with celastrol (1.25 µM) or wogonin (50 µM). Statistically significant improvements in the effect of combined therapy were found for the irinotecan (20 µM) and celastrol (1.25 µM) combination and irinotecan (20 µM) with wogonin (25 µM) in LOVO/DX cells. Minor additive effects of combined therapy were observed in LOVO cells. Inhibition of cell migration was seen in LOVO cells for all tested compounds, while only irinotecan (20 µM) and celastrol (1.25 µM) were able to inhibit LOVO/DX cell migration. Compared with single-drug therapy, a statistically significant inhibitory effect on cell migration was found for combinations of melatonin (2000 µM) with wogonin (25 µM) in LOVO/DX cells and irinotecan (5 µM) or melatonin (2000 µM) with wogonin (25 µM) in LOVO cells. Our research shows that adding melatonin, wogonin, or celastrol to standard irinotecan therapy may potentiate the anti-cancer effects of irinotecan alone in colon cancer treatment. Celastrol seems to have the greatest supporting therapy effect, especially for the treatment of aggressive types of colon cancer, by targeting cancer stem-like cells.
APA, Harvard, Vancouver, ISO, and other styles
7

Aoki, Masahiko, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, et al. "Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer." ESMO Open 4, no. 3 (May 2019): e000488. http://dx.doi.org/10.1136/esmoopen-2019-000488.

Full text
Abstract:
BackgroundNivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotecan.MethodsThe subjects of this retrospective study were patients with AGC with measurable lesions, and their tumour growth rates (TGR) during nivolumab or irinotecan were compared with those during prior therapy. HPD was defined as an increase in TGR more than twofold.Results34 and 66 patients received nivolumab and irinotecan in third or later line between June 2009 and September 2018 at our hospital; 22 patients receiving nivolumab had prior treatment with irinotecan, and one patient received irinotecan after nivolumab. Nivolumab and irinotecan showed no differences in disease control rates (38.2% and 34.8%) and in progression-free survival (PFS) (HR 1.1, 95% CI 0.7 to 1.6, p=0.802). The incidence of HPD was slightly higher after nivolumab (29.4%) than after irinotecan (13.5%) (p=0.0656), showing no differences in background between the patients with and without HPD. Compared between HPD and PD other than HPD after nivolumab, the HRs for PFS and overall survival (OS) were 1.1 (95% CI 0.5 to 2.7; p=0.756), and 2.1 (95% CI 0.7 to 5.8; p=0.168), but such clear difference in OS was not observed after irinotecan.ConclusionsHPD was observed more frequently after nivolumab compared with irinotecan, which was associated with a poor prognosis after nivolumab but not so clearly after irinotecan.
APA, Harvard, Vancouver, ISO, and other styles
8

Kciuk, Mateusz, Beata Marciniak, and Renata Kontek. "Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview." International Journal of Molecular Sciences 21, no. 14 (July 12, 2020): 4919. http://dx.doi.org/10.3390/ijms21144919.

Full text
Abstract:
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
APA, Harvard, Vancouver, ISO, and other styles
9

Sagawa, Tamotsu, Hironaga Satake, Koshi Fujikawa, Yukimasa Hatachi, Hisateru Yasui, Masahito Kotaka, Takeshi Kato, and Akihito Tsuji. "Phase Ib study of ramucirumab and irinotecan for metastatic gastric cancer previously treated with fluoropyrimidine with/without platina and taxane." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 155. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.155.

Full text
Abstract:
155 Background: Optimal salvage line chemotherapy for previously heavily treated advanced/ metastatic gastric cancer (AGC) is unknown, but treated with irinotecan in Japan. Ramucirumab, a human IgG-1 monoclonal antibody that targets the extracellular domain of VEGF receptor 2, is the first molecularly targeted agent proven to be effective in second-line therapy for AGC in combination with chemotherapy. Furthermore, combination chemotherapy with ramucirumab and irinotecan based regimen (FOLFIRI) is recognized as one of the promising regimens for metastatic colorectal cancer. To date, however, use of the ramucirumab plus irinotean regimen for AGC patients has not been investigated, and recommended doses (RD) of ramucirumab plus irinotecan for patients with AGC therefore remain unknown. The aim of this study was to determine the maximum tolerated dose (MTD) and RD for systemic chemotherapy with rumucirumab plus irinotecan for AGC previously treated with fluoropyrimidine with/without platina and taxane. Methods: Patients received systemic chemotherapy with ramucirumab (8mg/kg) and irinotecan on day 1, repeated every 2 weeks. A decrease in irinotecan dose was planned from start level 1 (irinotecan 150mg/m2). This trial was registered with the University Hospital Medical Network (UMIN no. 000018606). Results: Six patients were enrolled from August 2015 to September 2017. MTD was not reached at level 1. Irinotecan 150 mg/m2 in combination with ramucirumab 8mg/kg could be administered with acceptable toxicity, and all patients were treated at these doses. No DLT was observed at Level 1. No treatment-related death was observed. Adverse events of grade 3/4 were neutropenia (17%), anemia (17%), hyponatremia (17%), hypertension (17%). Five of the six patients were evaluable for efficacy based on the RECIST criteria, and response rate and disease control rate were 20% and 100%, respectively. Conclusions: Salvage chemotherapy with a ramucirumab plus irinotecan regimen was well tolerable for patients with previously heavily treated AGC. RD was defined as ramucirumab 8 mg/kg in combination with irinotecan 150 mg/m2/day. Clinical trial information: 000018606.
APA, Harvard, Vancouver, ISO, and other styles
10

Shun, Yu-Ting, Hsien-Yung Lai, Yi-Ting Chuang, and Hsuen-Fu Lin. "Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report." Clinical Medicine Insights: Case Reports 16 (January 2023): 117954762211503. http://dx.doi.org/10.1177/11795476221150354.

Full text
Abstract:
Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms. Though 2 cases of irinotecan-induced muscle twitching were reported but the successful treatment of this adverse event still not shown. We present a 24-year-old female patient with advanced colorectal cancer received bevacizumab and FOLFIRI (irinotecan + calcium leucovorin + 5-fluorouracil) treatment. Her right pectoralis major muscle presented with involuntary muscle twitching during the infusion of irinotecan at the sixth cycle of chemotherapy. The muscle twitching was slowly dissipated about 4 hours after the halted of irinotecan infusion. Then lorazepam 2 mg iv was injected before administration of irinotecan in an attempt to prevent the muscle twitching in the seventh cycle of chemotherapy. The patient did not report further muscle twitching. After that, lorazepam was routine administered before each cycle of FOLFIRI regiment. No any muscle twitching was observed after the use of lorazepam. This case provides valuable insight that muscle twitching can occur as rare irinotecan-related adverse effect. Benzodiazepine agonists, such as lorazepam, is the potential treatment of choice.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "IRINOTECAN CANCER TREATMENT"

1

Schiel, Marissa Ann. "Human carboxylesterase 2 splice variants expression, activity, and role in the metabolism of irinotecan and capecitabine /." Thesis, Connect to resource online, 2009. http://hdl.handle.net/1805/1905.

Full text
Abstract:
Thesis (Ph.D.)--Indiana University, 2009.
Title from screen (viewed on August 28, 2009). Department of Biochemistry and Molecular Biology, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): William Bosron. Includes vita. Includes bibliographical references (leaves 102-111).
APA, Harvard, Vancouver, ISO, and other styles
2

Hinkle, David T. "CORRELATING IRINOTECAN AND CAPECITABINE TREATMENT FOR COLORECTAL CANCER TO GENE EXPRESSION, POLYMORPHISMS, AND CLINICAL OUTCOMES." Thesis, 2011. http://hdl.handle.net/1805/2510.

Full text
Abstract:
Indiana University-Purdue University Indianapolis (IUPUI)
Colorectal cancer is the third most common type of cancer and the third most common cause of cancer-related mortality. There are three types of treatment available to patients, either individually or in combination. Treatments are radiation, chemotherapy, and surgery. In a Phase II clinical trial at IUSM, a multimodality approach was chosen. The patients with locally advanced rectal cancer received preoperative treatment with capecitabine and irinotecan (CPT-11) combination followed by chemoradiation with capecitabine and finally surgery to improve response and decrease local recurrence. Irinotecan and Capecitabine are both prodrugs activated in vivo to SN-38 and 5-FU, respectively. Identification of the molecular markers for 5-FU and Irinotecan efficacy and toxicity is important for the development of more efficient and less toxic treatment strategies for patients with colorectal cancer. The goal of this study was to determine the expression levels of the genes involved in activation and metabolism of capecitabine and irinotecan in pre and post treatment specimens from these patients. The genes quantitated by real-time PCR were carboxylesterase 1 and 2 (CES1 and CES2), thymidylate synthase (TS), β-glucoronidase (β-GUS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and topoisomerase I (Topo I). The UGT1A1*28 polymorphism in UDP glucuronosyltransferase 1 is associated with SN-38 toxicity. Therefore, the UGT1A1*28 polymorphism status in patients was determined by PCR-sequencing. Correlative analysis of gene expression and UGT1A1*28 mutation with clinical outcome in this Phase II study was completed.
APA, Harvard, Vancouver, ISO, and other styles
3

DAS, NIVEDITA. "IN SILICO SCREENING OF QUERCETIN ANALOGUES AS POTENTIAL INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA FOR DIARRHEA MITIGATION IN IRINOTECAN CANCER TREATMENT." Thesis, 2023. http://dspace.dtu.ac.in:8080/jspui/handle/repository/19909.

Full text
Abstract:
Diarrhea can be caused due to many reasons in an oncological patient. It could be due to radiation therapy, graft vs host infections, chemotherapeutic agents. Early diagnosis of causative agent can help to prevent diarrhea in cancer patients. Chemotherapeutic agents such as 5 fluorouracil with leucovorin, capecitabine and irinotecan are main causative agent of diarrhea. Loperamide and Octreotide are two recommended treatments for chemotherapy induced diarrhea. Loperamide can only treat grade 1 or 2 diarrhea, it becomes ineffective in severe cases of diarrhea. Octreotide is especially for treating grade 3 or 4 diarrhea but one drawback is that it requires hospitalization for fluid resuscitation due to dehydration in patients which thus increases the cost of treatment. The therapeutic potential of TNF- alpha inhibition for conditions including cancer, diabetes, and particularly autoimmune illnesses is significant. Even though there are several small molecule inhibitors of TNF- that have been discovered, no orally active treatment has yet been revealed that necessitates the urgent need for a small molecule drug against TNF- alpha. This research paper presents a comprehensive analysis of autodocking results obtained from virtual screening experiments conducted on a library of plant natural compound as inhibitor - Quercetin. The objective was to identify potential lead compounds with high binding affinities and favourable binding modes against the Tumor Necrosis Factor – alpha. Our findings reveal promising candidates for further investigation as potential therapeutics in the treatment of chemotherapy induced diarrhoea.
APA, Harvard, Vancouver, ISO, and other styles
4

Chen, Ming-Cheng, and 陳明正. "Molecular Mechanism of Resistance to Irinotecan in LoVo Colon Cancer Cells, Pharmacological Mechanism of Targeted Treatment by Thymoquinone and Mechanisms of Cancer Stem Cells and miRNAs." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/97204020698622003607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Messerer, Corrie Lynn. "Liposomal encapsulation of irinotecan and potential for the use of liposomal drug in the treatment of liver metastases associated with advanced colorectal cancer." Thesis, 2002. http://hdl.handle.net/2429/13284.

Full text
Abstract:
Colorectal cancer is the second leading cause of cancer mortality in North America, primarily because of a high incidence of hepatic metastases, which are relatively unresponsive to the systemic chemotherapy. Irinotecan, a camptothecin analogue recently approved for used in conjunction with 5-fluorouricil/leucovorin, is a marginal improvement but toxic and by no means curative. Liposomal drug formulations are argued to be more effective at treating liver-localised carcinomas when compared with their free drug counterparts, because of their intrinsic affinity for the liver and extended lifespan. This work examined the suitability o f a liposomal irinotecan formulation in the treatment of colorectal liver metastases. Irinotecan was encapsulated in DSPC/cholesterol liposomes using an ionophore-generated transmembrane proton gradient. After i.v. injection, liposomal drug was eliminated from the plasma much more slowly than free drag, and after 1 h circulating levels of liposome-associated drug were 10 fold greater. In addition, high-performance liquid chromography analysis of plasma samples revealed that liposome-associated irinotecan is protected from inactivating hydrolysis with > 80 % remaining in the active lactone form up to 24 h after administration. These improved pharmacokinetics observed for the liposomal drug were associated with increased efficacy in both solid tumour and orthotopic human models of colorectal metastases. Using a model (LS180) of colorectal metastases in SCID/RAG2M mice it was demonstrated that liposome-encapsulated drug was more effective at arresting tumour growth than was free drug. Further, in the human model of colorectal liver metastases (LS174T), liposomal irinotecan substantially increase life span relative to free drug with all members surviving long-term (75 days) as compared to a survival time of 30 and 50 days for the control and free drug treated groups. These results illustrate that liposomal encapsulation can substantially enhance the therapeutic activity of irinotecan, and emphasize the potential for liposomal irinotecan in the treatment of liver metastases.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "IRINOTECAN CANCER TREATMENT"

1

National Institute for Clinical Excellence. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. London: NICE, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

M, Lloyd Jones, and National Co-ordinating Centre for HTA (Great Britain), eds. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Alton: Core Research on behalf of NCCHTA, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lloyd, Jones M., National Co-ordinating Centre for HTA (Great Britain), and Health Technology Assessment Programme, eds. A Rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Southampton: NCCHTA, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "IRINOTECAN CANCER TREATMENT"

1

Saltz, Leonard B. "Irinotecan in the Treatment of Colorectal Cancer." In Colorectal Cancer, 513–24. Totowa, NJ: Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-160-2_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wagner, Lars. "Pediatric Neuroblastoma: Treatment with Oral Irinotecan and Temozolomide." In Pediatric Cancer, 209–14. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2418-1_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fiorentini, Giammaria, Silvia Ricci Lucchi, Petros Giovanis, Maurizio Cantore, Stefano Guadagni, and Giorgio Papiani. "Phase I Clinical Study of Irinotecan (CPT-11) Hepatic Arterial Infusion Chemotherapy in Hepatic Metastases from Colorectal Cancer: Preliminary Results." In Multi-Treatment Modalities of Liver Tumours, 223–28. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0547-1_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Oteyola, Ayodeji Ojo, Raffaele Pilla, Folasade Adesola Ola-Oladimeji, and Omotayo Fagbuaro. "Natural Products Application and Combination Therapy in Colorectal Cancer Treatment." In Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics, 72–94. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-9258-8.ch004.

Full text
Abstract:
Colorectal cancer (CRC) is one of the common types of cancer affecting humans. The treatment of CRC involves surgery and chemotherapy. CRC treatment using the conventional chemotherapeutics has a negative burden on the patient's health as a result of high toxicity, occurrence of side effects, and drug resistance. Therefore, there is a pressing need to discover more effective and efficient approaches and drugs for treating CRC. This chapter will shed more light on the conventional treatment of colorectal cancer. This chapter discusses the natural products that have anti-CRC effects such as the polyphenols (curcumin, resveratrol), irinotecan, Ganoderma lucidum, cannabinoids, flavonoids, and terpenes. Furthermore, this chapter also highlights the importance of combination chemotherapy (conventional therapy and natural products) in treating CRC. It is believed that this area of research could be a promising approach to minimize side effects and drug resistance linked to the conventional chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "IRINOTECAN CANCER TREATMENT"

1

Davidson, David, Yunzhe Wang, Raquel Aloyz, and Lawrence Panasci. "Abstract 4692: ABT-888 synergizes treatment of colon cancer cell lines with irinotecan." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4692.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Morano, Federica, Salvatore Corallo, Ludovic Barault, Monica Niger, Rosa Berenato, Roberto Moretto, Giovanni Fucà, et al. "Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Westover, David, Xiang Ling, Xiaojun Liu, Hong Lam, Celine Gongora, Maguy Del Rio, and Fengzhi Li. "Abstract 829: The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Giever, Thomas A., Paul S. Ritch, James P. Thomas, Lauren A. Wiebe, George B. Haasler, Mario G. Gasparri, David Johnstone, Candice A. Johnstone, Elizabeth M. Gore, and Ben George. "Abstract 813: A combination of cisplatin, irinotecan, and paclitaxel (CIP) as frontline treatment of patients with metastatic esophageal cancer (mEC)." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-813.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sachdev, Jasgit C., Ramesh K. Ramanathan, Natarajan Raghunand, Jaeyeon Kim, Stephan G. Klinz, Eliel Bayever, Jonathan B. Fitzgerald, and Ronald L. Korn. "Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-01-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Klinz, Stephan, Jinzi Zheng, Raquel De Souza, Manuela Ventura, Nancy Paz, David Hedley, David Jaffray, and Jonathan Fitzgerald. "Abstract B47: Nanoliposomal irinotecan (nal-IRI) is an active treatment and reduces hypoxia as measured through longitudinal imaging using [18F]FAZA-PET in an orthotopic patient-derived model of pancreatic cancer." In Abstracts: AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.panca16-b47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Moulder, S., M. Mita, C. Bradley, C. Rocha, and L. Harris. "Abstract P6-15-01: A Phase 1b Study To Assess the Safety and Tolerability of the PARP Inhibitor Iniparib (BSI-201) in Combination with Irinotecan for the Treatment of Patients with Metastatic Breast Cancer (MBC)." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-15-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sachdev, JC, RK Ramanathan, N. Raghunand, C. Anders, P. Munster, S. Minton, D. Northfelt, et al. "Abstract OT3-02-14: A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398)." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-ot3-02-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'IRINOTECAN CANCER TREATMENT' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography